<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38353557</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.</ArticleTitle><Pagination><StartPage>e0205023</StartPage><MedlinePgn>e0205023</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e02050-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.02050-23</ELocationID><Abstract><AbstractText Label="UNLABELLED">Cancer patients are at risk for severe coronavirus disease 2019 (COVID-19) outcomes due to impaired immune responses. However, the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is inadequately characterized in this population. We hypothesized that cancer vs non-cancer individuals would mount less robust humoral and/or cellular vaccine-induced immune SARS-CoV-2 responses. Receptor binding domain (RBD) and SARS-CoV-2 spike protein antibody levels and T-cell responses were assessed in immunocompetent individuals with no underlying disorders (<i>n</i> = 479) and immunocompromised individuals (<i>n</i> = 115). All 594 individuals were vaccinated and of varying COVID-19 statuses (i.e., not known to have been infected, previously infected, or "Long-COVID"). Among immunocompromised individuals, 59% (<i>n</i> = 68) had an underlying hematologic malignancy; of those, 46% (<i>n</i> = 31) of individuals received cancer treatment &lt;30 days prior to study blood collection. Ninety-eight percentage (<i>n</i> = 469) of immunocompetent and 81% (<i>n</i> = 93) of immunocompromised individuals had elevated RBD antibody titers (&gt;1,000 U/mL), and of these, 60% (<i>n</i> = 281) and 44% (<i>n</i> = 41), respectively, also had elevated T-cell responses. Composite T-cell responses were higher in individuals previously infected with SARS-CoV-2 or those diagnosed with Long-COVID compared to uninfected individuals. T-cell responses varied between immunocompetent vs carcinoma (<i>n</i> = 12) cohorts (<i>P</i> &lt; 0.01) but not in immunocompetent vs hematologic malignancy cohorts. Most SARS-CoV-2 vaccinated individuals mounted robust cellular and/or humoral responses, though higher immunogenicity was observed among the immunocompetent compared to cancer populations. The study suggests B-cell targeted therapies suppress antibody responses, but not T-cell responses, to SARS-CoV-2 vaccination. Thus, vaccination continues to be an effective way to induce humoral and cellular immune responses as a likely key preventive measure against infection and/or subsequent more severe adverse outcomes.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The study was prompted by a desire to better assess the immune status of patients among our cancer host cohort, one of the largest in the New York metropolitan region. Hackensack Meridian Health is the largest healthcare system in New Jersey and cared for more than 75,000 coronavirus disease 2019 patients in its hospitals. The John Theurer Cancer Center sees more than 35,000 new cancer patients a year and performs more than 500 hematopoietic stem cell transplants. As a result, the work was undertaken to assess the effectiveness of vaccination in inducing humoral and cellular responses within this demographic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Titova</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7136-7828</Identifier><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kan</LastName><ForeName>Veronica W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozy</LastName><ForeName>Tara</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6478-5690</Identifier><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shier</LastName><ForeName>Kileen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8646-5201</Identifier><AffiliationInfo><Affiliation>Quest Diagnostics, Secaucus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prakash</LastName><ForeName>Vittal P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Quest Diagnostics, Secaucus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starolis</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Quest Diagnostics, Secaucus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Quest Diagnostics, Secaucus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldgirsh</LastName><ForeName>Kira</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seoyeon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelliccia</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mccutchen</LastName><ForeName>Aamirah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Megalla</LastName><ForeName>Martinus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunning</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>John Theurer Cancer Center, Hackensack, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Harvey W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Quest Diagnostics, Secaucus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>William A</ForeName><Initials>WA</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Quest Diagnostics, Secaucus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlin</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0002-1268-5524</Identifier><AffiliationInfo><Affiliation>Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="Y">Hematologic Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">immunocompromised</Keyword><Keyword MajorTopicYN="N">post-vaccination</Keyword></KeywordList><CoiStatement>Quest Diagnostics authors are employees of Quest Diagnostics and own stock in Quest Diagnostics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>14</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38353557</ArticleId><ArticleId IdType="pmc">PMC10913742</ArticleId><ArticleId IdType="doi">10.1128/spectrum.02050-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Cancer and COVID-19. 2023. 
Division of cancer prevention and control, centers for disease control and prevention. Available from: https://www.cdc.gov/cancer/dcpc/about/</Citation></Reference><Reference><Citation>Loose D. 2009. Van de Wiele C: the immune system and cancer. Cancer Biother Radiopharm 24:369&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">19538060</ArticleId></ArticleIdList></Reference><Reference><Citation>Singson JRC, Kirley PD, Pham H, Rothrock G, Armistead I, Meek J, Anderson EJ, Reeg L, Lynfield R, Ropp S, Muse A, Felsen CB, Sutton M, Talbot HK, Havers FP, Taylor CA, Reingold A, Chai SJ, COVID-NET Surveillance Team . 2022. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 - COVID-NET, 10 States. MMWR Morb Mortal Wkly Rep 71:878&#x2013;884. doi:10.15585/mmwr.mm7127a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7127a3</ArticleId><ArticleId IdType="pmc">PMC9290380</ArticleId><ArticleId IdType="pubmed">35797216</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. 2020. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130:2620&#x2013;2629. doi:10.1172/JCI137244</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, Launay O. 2022. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect 28:163&#x2013;177. doi:10.1016/j.cmi.2021.09.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.09.036</ArticleId><ArticleId IdType="pmc">PMC8595936</ArticleId><ArticleId IdType="pubmed">35020589</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L-N, Liu P-P, Li X-G, Zhou S-J, Li H, Wang Z-Y, Shen F, Lu B-C, Long Y, Xiao X, Wang Z-D, Li D, Han H-J, Yu H, Zhou S-H, Lv W-L, Yu X-J. 2021. Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection. Front Microbiol 12:803031. doi:10.3389/fmicb.2021.803031</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.803031</ArticleId><ArticleId IdType="pmc">PMC8928406</ArticleId><ArticleId IdType="pubmed">35310397</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus J, Tse LPV, Frazier A, Baric R, Peters B, Greenbaum J, Ollmann Saphire E, Smith DM, Sette A, Crotty S. 2020. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183:996&#x2013;1012. doi:10.1016/j.cell.2020.09.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarbartolo S, Ranzani V, Bandera A, Gruarin P, Bevilacqua V, Putignano AR, Gobbini A, Galeota E, Manara C, Bombaci M, et al. . 2021. Integrated longitudinal Immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci Immunol 6:eabg5021. doi:10.1126/sciimmunol.abg5021</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg5021</ArticleId><ArticleId IdType="pubmed">34376481</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. 2022. The T cell immune response against SARS-CoV-2. Nat Immunol 23:186&#x2013;193. doi:10.1038/s41590-021-01122-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, Mu&#xf1;oz-Ruiz M, McKenzie DR, Hayday TS, Francos-Quijorna I, et al. . 2020. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 26:1623&#x2013;1635. doi:10.1038/s41591-020-1038-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1038-6</ArticleId><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent SJ, Khoury DS, Reynaldi A, Juno JA, Wheatley AK, Stadler E, John Wherry E, Triccas J, Sasson SC, Cromer D, Davenport MP. 2022. Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nat Rev Immunol 22:387&#x2013;397. doi:10.1038/s41577-022-00716-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00716-1</ArticleId><ArticleId IdType="pmc">PMC9047577</ArticleId><ArticleId IdType="pubmed">35484322</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O&#x2019;Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. 2022. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer 10:e004766. doi:10.1136/jitc-2022-004766</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2022-004766</ArticleId><ArticleId IdType="pmc">PMC9226983</ArticleId><ArticleId IdType="pubmed">35732350</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L, Park Y-J, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, et al. . 2020. Mapping neutralizing and Immunodominant sites on the SARS-Cov-2 spike receptor-binding domain by structure-guided high-resolution Serology. Cell 183:1024&#x2013;1042. doi:10.1016/j.cell.2020.09.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. . 2020. An mRNA vaccine against SARS-CoV-2 &#x2014; preliminary report. N Engl J Med 383:1920&#x2013;1931. doi:10.1056/NEJMoa2022483</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022483</ArticleId><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, et al. . 2021. Apostolidis SA, et al: mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374:abm0829. doi:10.1126/science.abm0829</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0829</ArticleId><ArticleId IdType="pmc">PMC9284784</ArticleId><ArticleId IdType="pubmed">34648302</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, et al. . 2022. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375:43&#x2013;50. doi:10.1126/science.abm3425</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, Indenbaum V, Mandelboim M, Doolman R, Amit S, Mendelson E, Ziv A, Huppert A, Rubin C, Freedman L, Kreiss Y. 2021. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med 9:999&#x2013;1009. doi:10.1016/S2213-2600(21)00220-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00220-4</ArticleId><ArticleId IdType="pmc">PMC8253545</ArticleId><ArticleId IdType="pubmed">34224675</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo C, Zhu A, et al. . 2021. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590:630&#x2013;634. doi:10.1038/s41586-020-03041-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C, Lifton M, McMahan K, Sciacca M, VanWyk H, Wu C, Yu J, Collier A-RY, Barouch DH. 2022. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron. Nature 603:493&#x2013;496. doi:10.1038/s41586-022-04465-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04465-y</ArticleId><ArticleId IdType="pmc">PMC8930761</ArticleId><ArticleId IdType="pubmed">35102312</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako D, et al. . 2021. SARS-CoV-2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv:2021.12.08.21267417. doi:10.1101/2021.12.08.21267417</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.08.21267417</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreiro P, Sanz JC, San Rom&#xe1;n J, P&#xe9;rez-Abeledo M, Carretero M, Meg&#xed;as G, Vi&#xf1;uela-Prieto JM, Ramos B, Canora J, Mart&#xed;nez-Peromingo FJ, Barba R, Zapatero A, Candel FJ. 2022. A pilot study for the evaluation of an interferon gamma release assay (IGRA) to measure T-cell immune responses after SARS-CoV-2 infection or vaccination in a unique cloistered cohort. J Clin Microbiol 60:e0219921. doi:10.1128/jcm.02199-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.02199-21</ArticleId><ArticleId IdType="pmc">PMC8925901</ArticleId><ArticleId IdType="pubmed">35020419</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, Randell P, Pria AD, Lightstone L, Xu X-N, Barclay W, McAdoo SP, Kelleher P, Willicombe M. 2021. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet 397:1178&#x2013;1181. doi:10.1016/S0140-6736(21)00502-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00502-X</ArticleId><ArticleId IdType="pmc">PMC7993933</ArticleId><ArticleId IdType="pubmed">33640037</ArticleId></ArticleIdList></Reference><Reference><Citation>Alejo JL, Mitchell J, Chang A, Chiang TPY, Massie AB, Segev DL, Makary MA. 2022. Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19. JAMA 327:1085&#x2013;1087. doi:10.1001/jama.2022.1393</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.1393</ArticleId><ArticleId IdType="pmc">PMC8814952</ArticleId><ArticleId IdType="pubmed">35113143</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidar G, Agha M, Bilderback A, Lukanski A, Linstrum K, Troyan R, Rothenberger S, McMahon DK, Crandall MD, Sobolewksi MD, et al. . 2022. Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions. Clin Infect Dis 75:e630&#x2013;e644. doi:10.1093/cid/ciac103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac103</ArticleId><ArticleId IdType="pmc">PMC8903515</ArticleId><ArticleId IdType="pubmed">35179197</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano L, Salmanton-Garc&#xed;a J, Marchesi F, L&#xf3;pez-Garc&#xed;a A, Lamure S, Itri F, Gomes-Silva M, Dragonetti G, Falces-Romero I, van Doesum J, et al. . 2022. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood 139:1588&#x2013;1592. doi:10.1182/blood.2021014124</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021014124</ArticleId><ArticleId IdType="pmc">PMC8577877</ArticleId><ArticleId IdType="pubmed">34748627</ArticleId></ArticleIdList></Reference><Reference><Citation>Marasco V, Carniti C, Guidetti A, Farina L, Magni M, Miceli R, Calabretta L, Verderio P, Ljevar S, Serpenti F, Morelli D, Apolone G, Ippolito G, Agrati C, Corradini P. 2022. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol 196:548&#x2013;558. doi:10.1111/bjh.17877</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17877</ArticleId><ArticleId IdType="pmc">PMC8653177</ArticleId><ArticleId IdType="pubmed">34649298</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VW, Curley HM, Fittall MW, et al. . 2020. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 395:1919&#x2013;1926. doi:10.1016/S0140-6736(20)31173-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31173-9</ArticleId><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al. . 2020. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 10:783&#x2013;791. doi:10.1158/2159-8290.CD-20-0422</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0422</ArticleId><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SH, Stuart B, Joseph-Pietras D, Johnson M, Campbell N, Kelly A, Jeffrey D, Turaj AH, Rolfvondenbaumen K, Galloway C, et al. . 2022. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nat Cancer 3:552&#x2013;564. doi:10.1038/s43018-022-00364-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-022-00364-3</ArticleId><ArticleId IdType="pmc">PMC9135622</ArticleId><ArticleId IdType="pubmed">35332334</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. 2021. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med 385:562&#x2013;566. doi:10.1056/NEJMsb2104756</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb2104756</ArticleId><ArticleId IdType="pmc">PMC8494465</ArticleId><ArticleId IdType="pubmed">34347959</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeway CA Jr T, Walport M. 2001. B-cell activation by armed helper T cells, immunobiology: the immune system in health and disease (Ed 5th). Garland Science, New York.</Citation></Reference><Reference><Citation>Hirzel C, Chruscinski A, Ferreira VH, L&#x2019;Huillier AG, Natori Y, Han SH, Cordero E, Humar A, Kumar D, Influenza in Transplant Study Group . 2021. Natural influenza infection produces a greater diversity of humoral responses than vaccination in immunosuppressed transplant recipients. Am J Transplant 21:2709&#x2013;2718. doi:10.1111/ajt.16503</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16503</ArticleId><ArticleId IdType="pubmed">33484237</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Wolzt M, Wagner OF, Binder CJ, Haslacher H. 2021. Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection. Eur J Clin Invest 51:e13632. doi:10.1111/eci.13632</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13632</ArticleId><ArticleId IdType="pmc">PMC8420280</ArticleId><ArticleId IdType="pubmed">34337738</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, Fontana M, Smit A, Sackville-West JE, Cutino-Moguel T, Maini MK, Chain B, Noursadeghi M, Brooks T, Semper A, Manisty C, Treibel TA, Moon JC, Valdes AM, McKnight &#xc1;, Altmann DM, Boyton R. 2021. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 372:1418&#x2013;1423. doi:10.1126/science.abh1282</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1282</ArticleId><ArticleId IdType="pmc">PMC8168614</ArticleId><ArticleId IdType="pubmed">33931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopoulos P, Pfeifer D, Bartholom&#xe9; K, Follo M, Timmer J, Fisch P, Veelken H. 2011. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 117:3836&#x2013;3846. doi:10.1182/blood-2010-07-299321</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-07-299321</ArticleId><ArticleId IdType="pubmed">21270444</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma M, Gentilcore G, Heimersson K, Mozaffari F, N&#xe4;sman-Glaser B, Young E, Rosenquist R, Hansson L, &#xd6;sterborg A, Mellstedt H. 2017. T cells in chronic iymphocytic ieukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 102:562&#x2013;572. doi:10.3324/haematol.2016.151100</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2016.151100</ArticleId><ArticleId IdType="pmc">PMC5394965</ArticleId><ArticleId IdType="pubmed">27927767</ArticleId></ArticleIdList></Reference><Reference><Citation>Oran DP, Topol EJ. 2020. Prevalence of asymptomatic SARS-Cov-2 infection: A narrative review. Ann Intern Med 173(5):362&#x2013;367. doi:10.7326/M20-3012</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3012</ArticleId><ArticleId IdType="pmc">PMC7281624</ArticleId><ArticleId IdType="pubmed">32491919</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, Ma K. 2021. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect 54:12&#x2013;16. doi:10.1016/j.jmii.2020.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.05.001</ArticleId><ArticleId IdType="pmc">PMC7227597</ArticleId><ArticleId IdType="pubmed">32425996</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>